Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | SGK1 | O00141 | 1/20 | 0.37 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | GUSB | P08236 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | DDO | Q99489 | 1/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.34 |
| ▸ | PTGES | O14684 | 1/20 | 0.34 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.34 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13649272 | 0.82 | JAK2 (0.42) | SGK1TNKSTNKS2JAK2GUSB | |
| SCHEMBL3843087 | 0.80 | TGFBR1 (0.45) | TGFBR1PTGESACVR1BACVRL1 | |
| SCHEMBL3841205 | 0.73 | APEX1 (0.35) | NR1I2TNKSPARP1TNKS2LMNA | |
| SCHEMBL13649319 | 0.73 | TGFBR1 (0.41) | LMNATGFBR1ACVR1BACVRL1 | |
| SCHEMBL8347926 | 0.73 | TGFBR1 (0.41) | LMNATGFBR1ACVR1BACVRL1 | |
| SCHEMBL3838487 | 0.72 | PDE4D (0.36) | HDAC3HDAC1HDAC2HDAC6TGFBR1 | |
| SCHEMBL2127203 | 0.68 | PRKD3 (0.47) | SGK1GUSBLMNATGFBR1PTGES | |
| SCHEMBL9257716 | 0.67 | HSD11B1 (0.43) | LMNA | |
| SCHEMBL6763833 | 0.66 | MAPK1 (0.39) | HDAC3HDAC1HDAC2HDAC6LMNA | |
| SCHEMBL16879343 | 0.66 | TGFBR1 (0.43) | TGFBR1ACVR1BACVRL1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9987277-B2 | Carboxamide 4-[(4-pyridyl)amino] pryimidines for the treatment of hepatitis C | JANSSEN SCIENCES IRELAND UC (IE) | 2018-06-05 | — | — | US | disclosed |
| US-9987277-B2 | Carboxamide 4-[(4-pyridyl)amino] pryimidines for the treatment of hepatitis C | JANSSEN SCIENCES IRELAND UC (IE) | 2018-06-05 | — | — | US | disclosed |
| US-9987277-B2 | Carboxamide 4-[(4-pyridyl)amino] pryimidines for the treatment of hepatitis C | JANSSEN SCIENCES IRELAND UC (IE) | 2018-06-05 | — | — | US | disclosed |
| EP-2097084-B1 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO] PYRIMIDINES FOR THE TREATMENT OF HEPATITIS C | JANSSEN R & D IRELAND (IE) | 2015-01-28 | — | — | EP | disclosed |
| EP-2097084-B1 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO] PYRIMIDINES FOR THE TREATMENT OF HEPATITIS C | JANSSEN R & D IRELAND (IE) | 2015-01-28 | — | — | EP | disclosed |
| US-20090247523-A1 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO]PYRIMIDINES USEFUL AS HCV INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2009-10-01 | — | — | US | disclosed |
| US-20090247523-A1 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO]PYRIMIDINES USEFUL AS HCV INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2009-10-01 | — | — | US | disclosed |
| US-20090247523-A1 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO]PYRIMIDINES USEFUL AS HCV INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2009-10-01 | — | — | US | disclosed |
| EP-2097084-A2 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO] PYRIMIDINES FOR THE TREATMENT OF HEPATITIS C | Tibotec Pharmaceuticals Ltd. (IE) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008040778-A2 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO] PYRIMIDINES FOR THE TREATMENT OF HEPATITIS C | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008040778-A2 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO] PYRIMIDINES FOR THE TREATMENT OF HEPATITIS C | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-04-10 | — | — | WO | disclosed |
| EP-1549316-A4 | INHIBITORS OF TFGbeta | SCIOS INC (US) | 2008-04-09 | — | — | EP | disclosed |
| US-20060281763-A1 | Carboxamide inhibitors of TGFbeta | SCIOS INC. | 2006-12-14 | — | — | US | disclosed |
| WO-2006105222-A2 | CARBOXAMIDE INHIBITORS OF TGFB | SCIOS INC. (US) | 2006-10-05 | — | — | WO | disclosed |
| EP-1549316-A1 | INHIBITORS OF TFG&bgr; | SCIOS INC. (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040132730-A1 | Inhibitors of TGFbeta | SCIOS, INC. | 2004-07-08 | — | — | US | disclosed |
| WO-2004024159-A1 | INHIBITORS OF TFGβ | SCIOS INC. (US) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004024159-A1 | INHIBITORS OF TFGβ | SCIOS INC. (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247523-A1 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO]PYRIMIDINES USEFUL AS HCV INHIBITORS | HAVCR2, EIF2AK2, MAVS | NR1I2 1333/4885SGK1 4688/4885TNKS 383/4885 |
| US-20040132730-A1 | Inhibitors of TGFbeta | TGFBR1, TGFBR2, TGFB1 | NR1I2 2420/4885SGK1 3159/4885TNKS 698/4885 |
| US-20060281763-A1 | Carboxamide inhibitors of TGFbeta | TGFBR1, TGFBR2, TGFB1 | NR1I2 1901/4885SGK1 4330/4885TNKS 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.